Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: CETUXIMAB, . Treffer: 30

2022

Boos, SL; Loevenich, LP; Vosberg, S; Engleitner, T; Öllinger, R; Kumbrink, J; Rokavec, M; Michl, M; Greif, PA; Jung, A; Hermeking, H; Neumann, J; Kirchner, T; Rad, R; Jung, P Disease Modeling on Tumor Organoids Implicates AURKA as a Therapeutic Target in Liver Metastatic Colorectal Cancer.
Cell Mol Gastroenterol Hepatol. 2022; 13(2): 517-540. Doi: 10.1016/j.jcmgh.2021.10.008 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Gerger, A; Eisterer, W; Fuxius, S; Bastian, S; Koeberle, D; Welslau, M; Sanoyan, DA; Maas, C; Uhlig, J; Fenchel, K; Greil, R; VON, DER, Heyde, E; Agocs, GR; Weide, R; Schwager, M; Reichenbach, F; Modest, DP; Fritsch, R Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma - MORSECRC.
Anticancer Res. 2022; 42(10):4773-4785 Doi: 10.21873/anticanres.15982
Web of Science PubMed FullText FullText_MUG

 

Sconocchia, G; Lanzilli, G; Cesarini, V; Silvestris, DA; Rezvani, K; Arriga, R; Caratelli, S; Chen, K; Dou, J; Cenciarelli, C; Toietta, G; Baldari, S; Sconocchia, T; De, Paolis, F; Aureli, A; Iezzi, G; Irno, Consalvo, M; Buccisano, F; Del, Principe, MI; Maurillo, L; Venditti, A; Ottaviani, A; Spagnoli, GC Direct CD32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment.
Life Sci Alliance. 2022; 5(12): Doi: 10.26508/lsa.202201590 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2021

Keil, F; Hartl, M; Altorjai, G; Berghold, A; Riedl, R; Pecherstorfer, M; Mayrbaurl, B; De Vries, A; Schuster, J; Hackl, J; Fureder, T; Melchardt, T; Burian, M; Greil, R Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial
EUR J CANCER. 2021; 151: 201-210. Doi: 10.1016/j.ejca.2021.03.051
Web of Science PubMed FullText FullText_MUG

 

Keil, M; Conrad, T; Becker, M; Keilholz, U; Yaspo, ML; Lehrach, H; Schütte, M; Haybaeck, J; Hoffmann, J Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data.
Cancers (Basel). 2021; 13(23): Doi: 10.3390/cancers13236018 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Schneider, R; Gademann, G; Ochel, HJ; Neumann, K; Jandrig, B; Hass, P; Walke, M; Schostak, M; Brunner, T; Christoph, F Functional and mutational analysis after radiation and cetuximab treatment on prostate carcinoma cell line DU145.
Radiat Oncol. 2021; 16(1): 137 Doi: 10.1186/s13014-021-01859-6 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2020

Arriga, R; Caratelli, S; Lanzilli, G; Ottaviani, A; Cenciarelli, C; Sconocchia, T; Spagnoli, GC; Iezzi, G; Roselli, M; Lauro, D; Coppola, A; Dotti, G; Ferrone, S; Sconocchia, G CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab.
Int J Cancer. 2020; 146(9):2531-2538 Doi: 10.1002/ijc.32618 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Caratelli, S; Arriga, R; Sconocchia, T; Ottaviani, A; Lanzilli, G; Pastore, D; Cenciarelli, C; Venditti, A; Del Principe, MI; Lauro, D; Landoni, E; Du, H; Savoldo, B; Ferrone, S; Dotti, G; Sconocchia, G In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab.
Int J Cancer. 2020; 146(1):236-247 Doi: 10.1002/ijc.32663 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2018

Dietz, A; Wichmann, G; Kuhnt, T; Pfreundner, L; Hagen, R; Scheich, M; Kölbl, O; Hautmann, MG; Strutz, J; Schreiber, F; Bockmühl, U; Schilling, V; Feyer, P; de Wit, M; Maschmeyer, G; Jungehülsing, M; Schroeder, U; Wollenberg, B; Sittel, C; Münter, M; Lenarz, T; Klussmann, JP; Guntinas-Lichius, O; Rudack, C; Eich, HT; Foerg, T; Preyer, S; Westhofen, M; Welkoborsky, HJ; Esser, D; Thurnher, D; Remmert, S; Sudhoff, H; Görner, M; Bünzel, J; Budach, V; Held, S; Knödler, M; Lordick, F; Wiegand, S; Vogel, K; Boehm, A; Flentje, M; Keilholz, U Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II.
Ann Oncol. 2018; 29(10): 2105-2114. Doi: 10.1093/annonc/mdy332 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2017

Lill, C; Bachtiary, B; Selzer, E; Mittlboeck, M; Thurnher, D A 5‑year update of patients with HPV positive versus negative oropharyngeal cancer after radiochemotherapy in Austria.
Wien Klin Wochenschr. 2017; 129(11-12):398-403 Doi: 10.1007/s00508-017-1171-5 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Schütte, M; Risch, T; Abdavi-Azar, N; Boehnke, K; Schumacher, D; Keil, M; Yildiriman, R; Jandrasits, C; Borodina, T; Amstislavskiy, V; Worth, CL; Schweiger, C; Liebs, S; Lange, M; Warnatz, HJ; Butcher, LM; Barrett, JE; Sultan, M; Wierling, C; Golob-Schwarzl, N; Lax, S; Uranitsch, S; Becker, M; Welte, Y; Regan, JL; Silvestrov, M; Kehler, I; Fusi, A; Kessler, T; Herwig, R; Landegren, U; Wienke, D; Nilsson, M; Velasco, JA; Garin-Chesa, P; Reinhard, C; Beck, S; Schäfer, R; Regenbrecht, CR; Henderson, D; Lange, B; Haybaeck, J; Keilholz, U; Hoffmann, J; Lehrach, H; Yaspo, ML Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors.
Nat Commun. 2017; 8(2):14262-14262 Doi: 10.1038/ncomms14262 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2015

Haymerle, G; Thurnher, D; Kadletz, L; Stanisz, I; Brunner, M; Kotowski, U; Enzenhofer, E; Heiduschka, G Assessment of caroverine as a potential chemotherapeutical agent in HNSCC cell lines.
Eur Arch Otorhinolaryngol. 2015; 272(11):3451-3456 Doi: 10.1007/s00405-014-3364-0
Web of Science PubMed FullText FullText_MUG

 

Hilbe, W; Pall, G; Kocher, F; Pircher, A; Zabernigg, A; Schmid, T; Schumacher, M; Jamnig, H; Fiegl, M; Gächter, A; Freund, M; Kendler, D; Manzl, C; Zelger, B; Popper, H; Wöll, E Multicenter Phase II Study Evaluating Two Cycles of Docetaxel, Cisplatin and Cetuximab as Induction Regimen Prior to Surgery in Chemotherapy-Naive Patients with NSCLC Stage IB-IIIA (INN06-Study).
PLoS One. 2015; 10(5):e0125364-e0125364 Doi: 10.1371/journal.pone.0125364 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Kaczirek, K; Ciuleanu, TE; Vrbanec, D; Marton, E; Messinger, D; Liegl-Atzwanger, B; Wrba, F; Knittelfelder, R; Lindner, E; Zielinski, CC; Streubel, B; Brodowicz, T FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Clin Colorectal Cancer. 2015; 14(2):91-98 Doi: 10.1016/j.clcc.2014.12.003
Web of Science PubMed FullText FullText_MUG

 

Selzer, E; Grah, A; Heiduschka, G; Kornek, G; Thurnher, D Primary radiotherapy or postoperative radiotherapy in patients with head and neck cancer: Comparative analysis of inflammation-based prognostic scoring systems.
Strahlenther Onkol. 2015; 191(6):486-494 Doi: 10.1007/s00066-014-0803-1
Web of Science PubMed FullText FullText_MUG

 

Stratigos, A; Garbe, C; Lebbe, C; Malvehy, J; del Marmol, V; Pehamberger, H; Peris, K; Becker, JC; Zalaudek, I; Saiag, P; Middleton, MR; Bastholt, L; Testori, A; Grob, JJ; European Dermatology Forum (EDF); European Association of Dermato-Oncology (EADO); European Organization for Research and Treatment of Cancer (EORTC) Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline.
Eur J Cancer. 2015; 51(14):1989-2007 Doi: 10.1016/j.ejca.2015.06.110
Web of Science PubMed FullText FullText_MUG

 

2014

Eisterer, W; De Vries, A; Öfner, D; Rabl, H; Koplmüller, R; Greil, R; Tschmelitsch, J; Schmid, R; Kapp, K; Lukas, P; Sedlmayer, F; Höfler, G; Gnant, M; Thaler, J; Austrian Breast and Colorectal Cancer Study Group (ABCSG) Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial.
Anticancer Res. 2014; 34(11):6767-6773
Web of Science PubMed FullText

 

Heiduschka, G; Grah, A; Oberndorfer, F; Seemann, R; Kranz, A; Kornek, G; Wrba, F; Thurnher, D; Selzer, E Significance of p16 expression in head and neck cancer patients treated with radiotherapy and cetuximab.
Strahlenther Onkol. 2014; 190(9):832-838 Doi: 10.1007/s00066-014-0652-y
Web of Science PubMed FullText FullText_MUG

 

Mohan, S; Heitzer, E; Ulz, P; Lafer, I; Lax, S; Auer, M; Pichler, M; Gerger, A; Eisner, F; Hoefler, G; Bauernhofer, T; Geigl, JB; Speicher, MR Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.
PLoS Genet. 2014; 10(3):e1004271-e1004271 Doi: 10.1371/journal.pgen.1004271 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Pichler, M; Winter, E; Ress, AL; Bauernhofer, T; Gerger, A; Kiesslich, T; Lax, S; Samonigg, H; Hoefler, G miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
J Clin Pathol. 2014; 67(3):198-203 Doi: 10.1136/jclinpath-2013-201904
Web of Science PubMed FullText FullText_MUG

 

Pircher, A; Gamerith, G; Amann, A; Reinold, S; Popper, H; Gächter, A; Pall, G; Wöll, E; Jamnig, H; Gastl, G; Wolf, AM; Hilbe, W; Wolf, D Neoadjuvant chemo-immunotherapy modifies CD4(+)CD25(+) regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients.
Lung Cancer. 2014; 85(1): 81-87. Doi: 10.1016/j.lungcan.2014.04.001
Web of Science PubMed FullText FullText_MUG

 

Pircher, A; Manzl, C; Fiegl, M; Popper, H; Pirker, R; Hilbe, W Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient.
Lung Cancer. 2014; 83(3): 408-410. Doi: 10.1016/j.lungcan.2013.12.007 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Stiegelbauer, V; Perakis, S; Deutsch, A; Ling, H; Gerger, A; Pichler, M MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
World J Gastroenterol. 2014; 20(33):11727-11735 Doi: 10.3748/wjg.v20.i33.11727 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2013

Keil, F; Selzer, E; Berghold, A; Reinisch, S; Kapp, KS; De Vries, A; Greil, R; Bachtiary, B; Tinchon, C; Anderhuber, W; Burian, M; Kasparek, AK; Elsäßer, W; Kainz, H; Riedl, R; Kopp, M; Kornek, G Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Eur J Cancer. 2013; 49(2):352-359 Doi: 10.1016/j.ejca.2012.08.004
Web of Science PubMed FullText FullText_MUG

 

2012

Henzler, T; Konstandin, S; Schmid-Bindert, G; Apfaltrer, P; Haneder, S; Wenz, F; Schad, L; Manegold, C; Schoenberg, SO; Fink, C Imaging of tumor viability in lung cancer: initial results using 23Na-MRI.
Rofo. 2012; 184(4):340-344 Doi: 10.1055/s-0031-1299277
Web of Science PubMed FullText FullText_MUG

 

2011

Lill, C; Kornek, G; Bachtiary, B; Selzer, E; Schopper, C; Mittlboeck, M; Burian, M; Wrba, F; Thurnher, D Survival of patients with HPV-positive oropharyngeal cancer after radiochemotherapy is significantly enhanced.
Wien Klin Wochenschr. 2011; 123(7-8):215-221 Doi: 10.1007/s00508-011-1553-z
Web of Science PubMed FullText FullText_MUG

 

2010

Zhang, W; Azuma, M; Lurje, G; Gordon, MA; Yang, D; Pohl, A; Ning, Y; Bohanes, P; Gerger, A; Winder, T; Hollywood, E; Danenberg, KD; Saltz, L; Lenz, HJ Molecular Predictors of Combination Targeted Therapies (Cetuximab, Bevacizumab) in Irinotecan-Refractory Colorectal Cancer (BOND-2 Study).
Anticancer Res. 2010; 30(10):4209-4217
Web of Science PubMed

 

2008

Skoda, C; Erovic, BM; Wachek, V; Vormittag, L; Wrba, F; Martinek, H; Heiduschka, G; Kloimstein, P; Selzer, E; Thurnher, D Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck.
Oncol Rep. 2008; 19(6):1499-1503
Web of Science PubMed

 

2006

Leibl, S; Bodo, K; Gogg-Kammerer, M; Hrzenjak, A; Petru, E; Winter, R; Denk, H; Moinfar, F Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study.
Gynecol Oncol. 2006; 101(1): 18-23. Doi: 10.1016/j.ygyno.2005.10.009
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2005

Moinfar, F; Gogg-Kamerer, M; Sommersacher, A; Regitnig, P; Man, YG; Zatloukal, K; Denk, H; Tavassoli, FA Endometrial stromal sarcomas frequently express epidermal growth factor receptor (EGFR, HER-1): potential basis for a new therapeutic approach.
AMER J SURG PATHOL. 2005; 29(4): 485-489. Doi: 10.1097%2F01.pas.0000155149.83541.24
Web of Science PubMed FullText FullText_MUG Google Scholar

 

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum